Price
$147.64
Increased by +0.52%
Dollar volume (20D)
60.02 M
ADR%
4.17
Earnings report date
Nov 10, 2025
Shares float
22.98 M
Shares short
3.48 M [15.15%]
Shares outstanding
28.94 M
Market cap
4.25 B
Beta
0.70
Price/earnings
29.85
20D range
130.50 159.00
50D range
127.99 159.00
200D range
122.80 207.84

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.

Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Reported date EPSChange YoY EstimateSurprise
Aug 4, 25 1.29
Increased by +143.40%
1.22
Increased by +5.74%
May 5, 25 1.20
Increased by +3.89 K%
1.03
Increased by +16.14%
Feb 24, 25 1.53
Increased by +410.00%
1.85
Decreased by -17.39%
Nov 4, 24 0.91
Increased by +231.88%
0.90
Increased by +1.11%
Aug 5, 24 0.53
Increased by +142.40%
0.58
Decreased by -8.62%
May 6, 24 0.03
Increased by +101.70%
0.15
Decreased by -80.00%
Feb 26, 24 0.30
Increased by +124.00%
-0.38
Increased by +178.95%
Nov 6, 23 -0.69
Increased by +41.03%
-0.29
Decreased by -137.93%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 96.04 M
Increased by +36.65%
38.33 M
Increased by +146.23%
Increased by +39.91%
Increased by +80.19%
Mar 31, 25 88.18 M
Increased by +94.88%
35.73 M
Increased by +3.73 K%
Increased by +40.52%
Increased by +1.87 K%
Dec 31, 24 91.14 M
Increased by +116.26%
45.48 M
Increased by +423.23%
Increased by +49.90%
Increased by +141.94%
Sep 30, 24 83.84 M
Increased by +879.91%
27.18 M
Decreased by -66.34%
Increased by +32.42%
Decreased by -96.56%
Jun 30, 24 70.28 M
Increased by +N/A%
15.57 M
Increased by +146.88%
Increased by +22.15%
Decreased by N/A%
Mar 31, 24 45.25 M
Increased by +N/A%
932.00 K
Increased by +102.06%
Increased by +2.06%
Decreased by N/A%
Dec 31, 23 42.14 M
Increased by +N/A%
8.69 M
Increased by +127.12%
Increased by +20.63%
Decreased by N/A%
Sep 30, 23 8.56 M
Increased by +N/A%
80.75 M
Increased by +370.51%
Increased by +943.75%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY